Indeed, clinical perspectives are continuously expanding with novel cell-based engineering strategies against CD19+ lymphoid tumours, many of which try to simultaneously coordinate checkpoint inhibition to enhance the function of adoptively transferred cells [220]. This evidence concerns the gene CD19 and lymphoid neoplasm.